# Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

> **NCT02267135** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 102 (actual)

## Conditions studied

- Chronic Scalp Psoriasis

## Interventions

- **BIOLOGICAL:** Secukinumab 300 mg
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02267135
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-29
- **Primary completion:** 2015-12-07
- **Final completion:** 2015-12-07
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267135, "Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02267135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*